- Theratechnologies plans to list on Nasdaq; royalties flowing from main drug The Canadian Press - Wed, 18 May, 2011
MONTREAL - Theratechnologies Inc. (TSX:TH) said Wednesday that royalty payments are starting to come in for its flagship drug Egrifta, approved by the U.S. Food and Drug Administration to treat excess abdominal fat in some HIV-infected patients.
- Oncolytics Biotech shrinks its first quarter loss to $3.9 million The Canadian Press - Thu, 12 May, 2011
CALGARY - Oncolytics Biotech Inc. (TSX:ONC) reports tighter $3.9-million loss in first quarter, compared to loss of $4.5 million in the same quarter last year. The company's cancer treatment Reolysin is currently in clinical trials.
- Anti-cancer therapy developer Oncolytics Biotech narrows Q1 loss to $4M The Canadian Press - Thu, 12 May, 2011
CALGARY - Oncolytics Biotech Inc. (TSX:ONC) has reported a narrowing of its first-quarter net loss as the development stage pharmaceutical company moves ahead with clinical trials for its proprietary anti-cancer therapy Reolysin.
- Oncolytics Biotech inks commercialization deal for its cancer drug The Canadian Press - Wed, 11 May, 2011
CALGARY - Oncolytics Biotech Inc. (TSX:ONC) says it has entered into a supply agreement with a division of Sigma-Aldrich Corp. for the commercial manufacture of its cancer treatment.
- Teens take biotech project to Ottawa Saskatoon StarPhoenix - Sun, 8 May, 2011
Anyone with a sweet tooth knows it would be nice to munch on carbohydrates without taking in so many calories.
- Labopharm posts bigger loss on costs from job cuts Reuters - Wed, 4 May, 2011
TORONTO (Reuters) - Canadian biotech Labopharm Inc , which is considering various strategic alternatives, posted a greater quarterly loss on Wednesday, hurt by costs associated with recent job cuts.
- Drugmaker Pfizer posts 10 per cent rise in Q1 profit on lower costs, taxes The Canadian Press - Tue, 3 May, 2011
TRENTON, N.J. - Pfizer Inc. reported flat first-quarter sales and shaved its revenue forecasts Tuesday as generic competition eats away at key drugs and pressure builds for the drugmaker to sell or spin off parts of the company.
- New push to spur drugs for rare diseases, even as moms toil to fill that void The Canadian Press - Mon, 25 Apr, 2011
WASHINGTON - Every other week, seven-year-old twins Addison and Cassidy Hempel have an experimental medicine injected into their spines in hopes of battling a rare, fatal disease.
- Amgen's 1st-quarter profit falls on higher costs, but bests Wall Street's forecast The Canadian Press - Wed, 20 Apr, 2011
NEW YORK, N.Y. - Amgen Inc., the world's biggest biotech company, said Wednesday that its first-quarter profit fell about 4 per cent as it boosted spending on the launch of bone drugs Prolia and Xgeva and late-stage drug research. But results still topped Wall Street expectations and the company reaffirmed its outlook for …
- Ceapro profits rise to $501,000 in 2010, sales increase to $5.6 million The Canadian Press - Wed, 20 Apr, 2011
EDMONTON - Biotech firm Ceapro Inc. (TSXV:CZO) says it rose to profitability in 2010 as its sales grew.
- Johnson & Johnson's Q1 profit falls 23 per cent on higher costs; co. raises full-year outlook The Canadian Press - Tue, 19 Apr, 2011
Health care giant Johnson & Johnson's revenue rebounded but its profit dropped 23 per cent in the first quarter because of higher costs for product recalls and litigation.
- Microsoft vs. i4i case at U.S. Supreme Court has big implications for patent law The Canadian Press - Mon, 18 Apr, 2011
MONTREAL - A fight between small Canadian company i4i and software giant Microsoft Court is going all the way to the U.S. Supreme Court in a case that could challenge how patent laws protect exclusive technology.
- Montreal's Anachemia Canada being acquired by U.S.-based VWR International The Canadian Press - Mon, 18 Apr, 2011
RADNOR, Pa. - VWR International LLC, a global distributor of laboratory supplies and services, said Monday its is acquiring Montreal-based Anachemia Canada Inc.
- Microsoft vs. i4i case at U.S. Supreme Court has big implications for patent law The Canadian Press - Sun, 17 Apr, 2011
MONTREAL - A fight between small Canadian company i4i and software giant Microsoft Corp. is going all the way to the U.S. Supreme Court in a case that could challenge how patent laws protect exclusive technology.
- Sanofi-Aventis completes $20.1 billion buyout of Genzyme The Canadian Press - Fri, 8 Apr, 2011
NEW YORK, N.Y. - Sanofi-Aventis said Friday it has completed its $20.1 billion buyout of specialty drugmaker Genzyme Corp.
- Johnson & Johnson agrees to pay $70M to settle federal charges of bribing foreign doctors The Canadian Press - Fri, 8 Apr, 2011
WASHINGTON - Pharmaceutical giant Johnson & Johnson has agreed to pay $70 million to settle civil and criminal charges of bribing doctors in Europe and paying kickbacks to the Iraqi government to illegally obtain business.
- US researcher warning about genetically modified crops spreads, but scientists question claim The Canadian Press - Fri, 1 Apr, 2011
DES MOINES, Iowa - The widespread Internet posting of a letter by a retired university researcher who says he has linked genetically modified corn and soybeans to crop diseases and abortions and infertility in livestock has raised concern among scientists that the public will believe his unsupported claim is true.
An experimental patch could help desensitize people with peanut allergies, … More »Peanut allergy patch investigated
or 
feeds.